
Identification
Screening
Grouping
Included
Records identified through hospital information system (N = 219)
Hospitalized between 2018.01 and 2020.01
Diagnosis of acute heart failure
NT-proBNP > 400 ng/mL or BNP > 125ng/ml
Sinus heart rates > 70 bpm
Excluded
Age <16 years (N = 7)
Estimated GFR < 30 ml/min, N = 13)
Alcoholic cardiomyopathy (N = 2)
Hyperthyroid cardiomyopathy (N = 3)
Moderate-severe anaemia (N = 4)
Advanced atrioventricular block (N = 1)
Advanced malignant tumours (N = 4)
Severe valvular diseases without surgical treatment (N = 2)
Severe coronary stenosis without revascularization (N = 5)
Collect baseline data (N = 178)
Incomplete clinical information excluded (N = 10)
Screened baseline data (N = 168)
Group of reference (N = 67)
Group of ivabradine (N = 101)
Excluded
Lost follow up within 3 months (N = 4)
Excluded
≥ 4 weeks from admission to initiation of ivabradine (N = 3)
Initiation of ivabradine during a status of haemodynamic instability (N = 9)
Cessation within 7 days of ivabradine treatment (N = 8)
Initiation of ivabradine after discharge (N = 11)
Included in a perspective trial of ivabradine (N = 2)
Lost follow up within 3 months (N = 5)
Patients included
Group of refer (N = 63)
Group of ivabradine (N = 63)
Clinic and telephone follow up
Recording adverse events
Medical strategies and cardiac function